The French firm has a lead metastatic colorectal cancer vaccine candidate headed for Phase I/IIA trials, in which it will explore ways of predicting response.
Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.
The firms will collaborate on two lead programs and up to five future targets in other diseases, with NanoVation eligible for up to $600 million in payments from Novo Nordisk.
Researchers analyzed molecular and particulate matter exposure data on nearly 9,000 NSCLC patients in France and confirmed a link reported by UK scientists in 2022.
Researchers at the ESMO Congress presented data showing better responses on dual-checkpoint blockade in the biomarker-defined ...
The drug is approved in combination with an aromatase inhibitor as adjuvant therapy for breast cancer patients at high risk of recurrence.
Patients on therapies recommended by an MTB had better progression-free survival and overall response rates than those on standard-of-care therapy.
The firms will share data from the HERTHENA-Lung02 trial, in which patritumab deruxtecan improved patients' progression-free survival versus chemo.
The company said the single-arm multicenter Phase II trial may support accelerated approval for the RP-A501 gene therapy in the US.
The adaptive basket trial, which matches patients to treatments based on complex biomarker signatures, could help shape ...
At ESMO, Multiple Enhertu Studies Highlight Challenges of Selecting, Managing Breast Cancer Patients
Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.
The firm is testing azenosertib as a single agent and in combination with other drugs in various solid tumors and looking at response biomarkers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback